ArticleLasers in medical science2026
Photobiomodulation in acute rejection of fetal intestinal grafts: morphological aspects and lymphocyte activation.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute rejection remains a significant challenge in organ transplantation. Photobiomodulation (PBM) has demonstrated anti-inflammatory and regenerative properties, suggesting potential benefits in modulating immune responses. This study aimed to evaluate the effects of PBM on fetal intestinal transplantation in mice. The study was conducted in two phases. In the first phase, 77 mice were utilized to assess histological outcomes. Fetal intestines from pregnant C57BL/6 mice were transplanted into BALB/c recipients, forming allogeneic groups (ALLO-GTx) with or without PBM (ALLO-GTxPBM), and syngeneic controls (RG). PBM was applied transcutaneous at the graft site immediately post-surgery (660 nm, 40 J/cm², 1.5 J). Grafts were collected on postoperative days 3, 5, and 7 for hematoxylin-eosin staining and evaluated using Aubert's criteria. In the second phase, spleens from 30 transplanted mice were analyzed on day 7 via flow cytometry for lymphocyte activation markers (CD4+, CD8+, CD44, CD69, CD54, CD62L). PBM significantly reduced rejection scores on days 5 (3.5 [3-9] vs. 12 [10-13.8]; p = 0.0006) and 7 (p = 0.0096), and enhanced graft development (p = 0.0079). Flow cytometry revealed decreased activation of CD4 + CD44+CD69+ (9.08% to 3.15%) and CD8 + CD44+CD69+ (1.53% to 0.90%) T cells in PBM-treated animals. Additionally, lower expression levels of CD62L + and CD54 were observed, indicating immunomodulatory effects. PBM improved graft viability and mitigated acute rejection in fetal intestinal transplantation in mice. These findings support further investigation into PBM as a therapeutic strategy to modulate immune responses in transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.